The Journal of dermatological treatment
-
Review Meta Analysis
Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan.
Biological therapies have recently been introduced for patients with moderate to severe psoriasis in Japan. ⋯ Ustekinumab was a more cost-efficient biological therapy than adalimumab or infliximab for psoriasis patients in a Japanese setting.
-
To provide an overview of the current evidence regarding off-label treatment of hidradenitis suppurativa (HS) with TNF-α inhibitors, a systematic search was performed in MEDLINE, EMBASE and CENTRAL. Any type of original article concerning HS patients treated with infliximab, etanercept and/or adalimumab was included. No language restriction was applied. ⋯ Infliximab should be preferred based on the most encouraging results regarding efficacy and expenses. Also adalimumab seems promising when administered in higher doses. The use of etanercept should be discouraged.